# AZA-TDC CAPSULES FOR USE IN CLINICAL TRIAL

> **NIH NIH N01** · IRISYS, INC. · 2022 · $177,135

## Abstract

AZA-TDC CAPSULES FOR USE IN CLINICAL TRIAL FOR POSSIBLE CANCER TREATMENT. THE DRUG PRODUCT (DP) WILL BE A 4 MG STRENGTH CAPSULE WHICH IS NOT AVAILABLE

## Key facts

- **NIH application ID:** 10710313
- **Project number:** 75N98019D00058-0-759102200001-1
- **Recipient organization:** IRISYS, INC.
- **Principal Investigator:** ROBERT GIANNINI
- **Activity code:** N01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $177,135
- **Award type:** —
- **Project period:** 2021-11-19 → 2025-11-18

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10710313

## Citation

> US National Institutes of Health, RePORTER application 10710313, AZA-TDC CAPSULES FOR USE IN CLINICAL TRIAL (75N98019D00058-0-759102200001-1). Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/grant/nih/10710313. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*